-transparent.png){kind=logo}
Twenty hypertensive patients entered a crossover, placebo-controlled study of prazosin and labetalol that was designed to compare treatment effects on blood pressure control and lipid parameters. Both drugs significantly reduced sitting and standing systolic and diastolic blood pressures (p less than or equal to 0.01). No significant differences were noted between treatment groups in total cholesterol, high-density lipoprotein cholesterol, or very low-density lipoprotein cholesterol levels. However, a trend toward an increase in low-density lipoprotein cholesterol levels was seen during therapy with labetalol, whereas in contrast, no such effect was seen during treatment with prazosin.
J P Farry, and
S J Fischl, and
M J Tighe, and
M J Krell
January 1988,
European journal of clinical pharmacology,
J P Farry, and
S J Fischl, and
M J Tighe, and
M J Krell
January 1989,
The American journal of medicine,
J P Farry, and
S J Fischl, and
M J Tighe, and
M J Krell
January 1994,
Journal of cardiovascular pharmacology,
J P Farry, and
S J Fischl, and
M J Tighe, and
M J Krell
December 1990,
Journal of clinical pharmacology,
J P Farry, and
S J Fischl, and
M J Tighe, and
M J Krell
October 2014,
Zhonghua nei ke za zhi,
J P Farry, and
S J Fischl, and
M J Tighe, and
M J Krell
March 2019,
Medicine,
J P Farry, and
S J Fischl, and
M J Tighe, and
M J Krell
September 2013,
Zhonghua nei ke za zhi,
J P Farry, and
S J Fischl, and
M J Tighe, and
M J Krell
January 1990,
Clinical therapeutics,
J P Farry, and
S J Fischl, and
M J Tighe, and
M J Krell
April 2013,
Zhonghua xin xue guan bing za zhi,
J P Farry, and
S J Fischl, and
M J Tighe, and
M J Krell
January 2001,
Current medical research and opinion,
